Point-of-Care Diagnostics Market: Research Report, Size, Share, Growth and Forecast to 2031

Point-of-Care Diagnostics Market Overview:

The Point of Care (POC) Molecular Diagnostics Market is experiencing steady expansion, driven by the global shift toward rapid, decentralized, and patient-centric healthcare. These diagnostic solutions enable real-time disease detection at or near the patient site, eliminating the delays associated with centralized laboratory testing.

The increasing prevalence of genetic disorders is likely to drive the diagnostics market in the coming years. According to a report published by the CDC, congenital heart defects were the most common birth defects in the U.S., affecting approximately 1% of births every year. Early detection of genetic variations via prenatal testing can help in rapid disease diagnosis, prevention, and selection of suitable treatment. Changing lifestyle and environmental factors are increasing the incidence of genetic diseases. The incidence of breast and ovarian cancers is increasing in many regions. For instance, according to the Breast Cancer Research Foundation, in 2023, approximately 300,590 people are expected to be diagnosed with breast cancer in the U.S. Thus, the growing incidence of various diseases is likely to boost the market over the forecast period.

Download Sample PDF Copy: https://meditechinsights.com/point-of-care-diagnostics-market/request-sample/

Moreover, the geriatric population is rapidly increasing across the globe. According to a UN report, in 2020, there were about 727 million people aged 65 & above globally. In addition, the number of individuals aged 80 and above is projected to double by 2050, which is over 1.5 billion. Aging has become a substantial risk factor for numerous diseases, including obesity and diabetes, which, in turn, significantly increases the risk of infectious diseases. The geriatric population is susceptible to numerous diseases such as cancer, cardiovascular diseases, obesity, neurological disorders, and diabetes. Thus, the growing geriatric population globally is anticipated to be a high-impact rendering driver of the point of care diagnostics market.

Market Insights

The global market growth reflects increasing adoption across hospitals, clinics, home-care settings, and remote healthcare environments. Infectious disease testing dominates the market, accounting for nearly half of total demand, owing to the need for rapid diagnosis of conditions such as influenza, COVID-19, HIV, and other respiratory infections.

Technologically, PCR-based platforms continue to lead due to their high sensitivity and reliability, while emerging technologies such as isothermal amplification and genetic sequencing are gaining traction for faster and more portable testing solutions.

Market Concentration & Characteristics

Market growth stage is high, and the pace of growth is accelerating. The industry is characterized by a high degree of innovation owing to rapid technological advancements and the launch of novel products by key players in the market. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Innovation in HbA1c testing technology has led to the development of breakthrough products that set new standards in diabetes care. For instance, in January 2024, the FDA approved Qvin's Q-Pad A1c Test System for measuring hemoglobin A1c in diabetes patients using menstrual blood. The system includes the Q-Pad A1c Test and Q-Pad Kit, designed for individuals aged 18 and older to collect menstrual blood samples using the Q-Pad, an unscented pad with an embedded blood collection strip.

The point of care diagnostics industry experiences a high level of mergers and acquisitions (M&A), as companies pursue strategic partnerships and acquisitions to expand product portfolios, enter new market segments, and strengthen their global presence. Large players often acquire smaller, innovative firms to integrate advanced technologies, such as molecular diagnostics and digital health solutions, into their offerings. For instance, in March 2023, Werfen acquired Immucor, Inc. to establish a strong presence in Specialized Diagnostics. The deal was valued at USD 2 billion. Similarly, in May 2023, Siemens Healthcare GmbH partnered with Unilabs, with an agreed value exceeding USD 200 million. Within the partnership, Unilabs will purchase 400 laboratory analyzers to improve patient care infrastructure. Operating players in point of care diagnostics market leverage these strategies to increase their product capabilities and promote the reach of their offerings.

Key Growth Drivers

Rising Burden of Infectious and Chronic Diseases

The increasing prevalence of infectious diseases worldwide is a primary factor fueling demand for rapid diagnostic tools. Point-of-care molecular tests allow early detection and timely intervention, which is critical for disease control and prevention.

Demand for Rapid and Decentralized Testing

Healthcare systems are shifting toward decentralized diagnostics, enabling testing outside traditional laboratories. This reduces turnaround time and supports immediate clinical decision-making, especially in emergency and critical care settings.

Technological Advancements

Innovations in microfluidics, portable PCR systems, multiplex testing, and handheld diagnostic devices are significantly enhancing the accuracy, speed, and usability of POC molecular diagnostics. These advancements are making devices more accessible in both developed and resource-limited settings.

Growth of Home-Based and OTC Testing

The rise of over-the-counter (OTC) and self-testing kits is transforming the diagnostics landscape. Consumers increasingly prefer convenient, at-home testing solutions, which reduce hospital visits and healthcare costs while promoting early disease detection.

Expansion into New Clinical Applications

While infectious diseases remain the primary application, the market is expanding into oncology, genetic testing, and antimicrobial resistance detection, increasing the overall scope and demand for molecular diagnostics.

Integration with Digital Health and Telemedicine

Modern POC devices are being integrated with digital health platforms and electronic health records (EHRs), enabling real-time data sharing, remote monitoring, and improved patient management.

Increasing Focus on Rural and Resource-Limited Settings

Portable, battery-operated diagnostic devices are addressing healthcare gaps in rural and underserved regions, particularly in emerging economies. This is significantly boosting adoption in Asia-Pacific and other developing regions.

Point-of-care diagnostics refer to medical tests conducted outside centralized laboratories—typically at or near the patient’s location. Designed to deliver fast and convenient results, these tests enable healthcare professionals to make immediate clinical decisions. Key advantages include rapid turnaround times, accessibility across varied healthcare settings, minimal training requirements, and the ability to initiate prompt treatment. POC diagnostics are widely used for infectious diseases, cardiovascular conditions, pregnancy detection, and diabetes management. Portable devices enhance testing in remote and resource-constrained environments, while decentralized testing improves overall healthcare access. Common examples include rapid strep tests, pregnancy tests, and blood glucose monitoring systems. As innovation continues, emerging POC technologies are advancing patient-centric care by improving diagnostic speed, efficiency, and accessibility.

Download Sample PDF Copy: https://meditechinsights.com/point-of-care-diagnostics-market/request-sample/

Accelerating Diagnosis Beyond Traditional Laboratories

The growing need for timely and accurate diagnosis of chronic and infectious diseases has significantly increased demand for advanced POC testing solutions. Rising global cases of HIV, hepatitis, influenza, and tuberculosis have underscored the urgency of rapid detection and early treatment initiation. POC diagnostics play a vital role in containing disease spread and improving patient outcomes by delivering immediate results in clinical and community settings.

For example, in June 2023, Sysmex Corporation launched Europe’s first POC testing system capable of determining antimicrobial susceptibility within 30 minutes. The system analyzes urine samples from patients suspected of urinary tract infections (UTIs), detecting bacterial presence and assessing antimicrobial effectiveness.

This shift reflects a broader movement toward proactive healthcare models, where rapid diagnosis supports disease control, targeted therapy, and improved population health management.

Technological Advancements Driving Next-Generation POC Testing

Recent breakthroughs are reshaping POC diagnostics. Multiplexing technologies now allow simultaneous detection of multiple biomarkers at the patient’s bedside, significantly improving diagnostic efficiency. Additionally, smartphone-enabled diagnostics are fostering cost-effective mobile healthcare solutions and personalized medicine by integrating testing capabilities into everyday devices.

In November 2022, LumiraDx Limited announced the commercial expansion of its HbA1c test for professional use. Integrated with the LumiraDx Platform, the test supports diabetes monitoring and screening across diverse care settings.

Further innovation includes the development of paper-based assays (PBAs) and lab-on-a-chip (LOC) platforms. PBAs offer affordability and simplicity, while LOC technologies provide compact, automated, and integrated diagnostic systems. Advances in reagent stabilization now allow long-term storage at ambient temperatures, improving device practicality in varied environments. Collectively, these technologies are enhancing the robustness, accessibility, and scalability of POC testing worldwide.

Key Challenges in the Market

Despite strong growth prospects, the POC diagnostics market faces several challenges. Regulatory compliance remains complex due to the diverse range of devices requiring stringent validation for accuracy and reliability. Integration into existing healthcare systems can also be difficult. Additionally, cost constraints—particularly in low-resource settings—pose barriers to widespread adoption. Overcoming these regulatory, operational, and economic hurdles is critical for sustained market expansion.

Regional Market Insights

North America currently leads the POC diagnostics market, driven by favorable government policies, high awareness of self-testing, and a strong prevalence of lifestyle-related diseases. In contrast, the Asia-Pacific region is expected to record the fastest growth. This expansion is supported by population growth, increasing numbers of diagnostic laboratories, rising healthcare expenditure, and the growing presence of domestic manufacturers producing diagnostic kits and reagents.

Browse Report: https://meditechinsights.com/point-of-care-diagnostics-market/

Competitive Landscape

Key players operating in the market include:

• Abbott Laboratories
• Siemens Healthineers
• F. Hoffmann-La Roche Ltd
• BD (Becton, Dickinson and Company)
• Trinity Biotech
• Nova Biomedical
• Quidel Corporation
• Danaher Corporation

Strategic Growth Initiatives

Market participants are leveraging both organic and inorganic strategies—including partnerships, collaborations, and acquisitions—to strengthen their positions.

In January 2023, Trinity Biotech entered a five-year strategic partnership with imaware, appointing Trinity as the lab testing partner. The collaboration aims to process more than 650,000 test kits annually by the third year at its New York-based reference laboratory, delivering integrated diagnostic and follow-up confirmatory testing solutions.

Earlier, in January 2021, Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Mesa Biotech, Inc., expanding its molecular diagnostics portfolio with Mesa’s rapid PCR platform for detecting infectious diseases such as SARS-CoV-2 and Influenza A and B.

Related Report:

Tricuspid Valve Repair Market           https://www.pharmiweb.com/press-release/2026-05-18/tricuspid-valve-repair-market-will-generate-booming-growth-opportunities-to-2031

Hematology Market   https://www.pharmiweb.com/press-release/2026-05-18/hematology-market-size-share-key-developments-innovations-and-opportunities-through-2031

Lipid Nanoparticles (LNP) CDMO Market      https://www.pharmiweb.com/press-release/2026-05-19/lipid-nanoparticles-lnp-cdmo-market-growth-is-attributed-to-the-increasing-demand-for-sirna-lipid-nanoparticle

NICU Genetic Testing Market https://www.pharmiweb.com/press-release/2026-05-19/nicu-genetic-testing-market-empowering-personalized-health-innovating-genetic-testing-services-for-better-patient-outcomes

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com